Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Core Insights - Genprex, Inc. announced positive preclinical data for Reqorsa® Gene Therapy targeting ALK-EML4 positive non-small cell lung cancer (NSCLC) [1][3][4] - The data was presented at the 2025 AACR-NCI-EORTC International Conference, highlighting the potential of Reqorsa in combination with Alectinib to improve treatment outcomes [2][3] Company Overview - Genprex is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing innovative technologies to deliver disease-fighting genes [7][9] - The company's lead product, Reqorsa, is designed to deliver the TUSC2 gene specifically to cancer cells while minimizing effects on normal tissues [6][9] Research Findings - Preclinical studies demonstrated that Reqorsa can upregulate the tumor suppressor gene TUSC2, inducing apoptosis in ALK+ NSCLC cells, including those resistant to Alectinib [4][6] - The combination of Reqorsa and Alectinib resulted in longer survival rates in mouse models compared to control groups, supporting the potential for clinical trials in ALK-positive lung cancer [3][4] Clinical Development - Reqorsa is currently being evaluated in two clinical trials for NSCLC and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [9] - The SCLC program has also received Orphan Drug Designation from the FDA, indicating its potential to address unmet medical needs [9]